358 related articles for article (PubMed ID: 29084989)
1. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38
Fumey W; Koenigsdorf J; Kunick V; Menzel S; Schütze K; Unger M; Schriewer L; Haag F; Adam G; Oberle A; Binder M; Fliegert R; Guse A; Zhao YJ; Cheung Lee H; Malavasi F; Goldbaum F; van Hegelsom R; Stortelers C; Bannas P; Koch-Nolte F
Sci Rep; 2017 Oct; 7(1):14289. PubMed ID: 29084989
[TBL] [Abstract][Full Text] [Related]
2. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
3. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
4. CD38-specific nanobodies allow
Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
[TBL] [Abstract][Full Text] [Related]
5. Immuno-targeting the multifunctional CD38 using nanobody.
Li T; Qi S; Unger M; Hou YN; Deng QW; Liu J; Lam CMC; Wang XW; Xin D; Zhang P; Koch-Nolte F; Hao Q; Zhang H; Lee HC; Zhao YJ
Sci Rep; 2016 Jun; 6():27055. PubMed ID: 27251573
[TBL] [Abstract][Full Text] [Related]
6. Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.
Baum N; Eggers M; Koenigsdorf J; Menzel S; Hambach J; Staehler T; Fliegert R; Kulow F; Adam G; Haag F; Bannas P; Koch-Nolte F
Front Immunol; 2021; 12():703574. PubMed ID: 34539634
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
Cho N; Ko S; Shokeen M
Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
Hambach J; Riecken K; Cichutek S; Schütze K; Albrecht B; Petry K; Röckendorf JL; Baum N; Kröger N; Hansen T; Schuch G; Haag F; Adam G; Fehse B; Bannas P; Koch-Nolte F
Cells; 2020 Jan; 9(2):. PubMed ID: 32013131
[TBL] [Abstract][Full Text] [Related]
10. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2559. PubMed ID: 30459772
[TBL] [Abstract][Full Text] [Related]
11. Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients.
Li T; Li SL; Fang C; Hou YN; Zhang Q; Du X; Lee HC; Zhao YJ
Anal Chim Acta; 2018 Oct; 1029():65-71. PubMed ID: 29907292
[TBL] [Abstract][Full Text] [Related]
12. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.
Hambach J; Fumey W; Stähler T; Gebhardt AJ; Adam G; Weisel K; Koch-Nolte F; Bannas P
Front Immunol; 2022; 13():838406. PubMed ID: 35651607
[TBL] [Abstract][Full Text] [Related]
13. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
16. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
Yu T; Qiao C; Lv M; Tang L
BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
[TBL] [Abstract][Full Text] [Related]
17. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
18. CD38 as a PET Imaging Target in Lung Cancer.
Ehlerding EB; England CG; Jiang D; Graves SA; Kang L; Lacognata S; Barnhart TE; Cai W
Mol Pharm; 2017 Jul; 14(7):2400-2406. PubMed ID: 28573863
[TBL] [Abstract][Full Text] [Related]
19. ImmunoPET imaging of CD38 in murine lymphoma models using
Kang L; Jiang D; England CG; Barnhart TE; Yu B; Rosenkrans ZT; Wang R; Engle JW; Xu X; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1372-1381. PubMed ID: 29450576
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]